Yes. CareFirst BlueCross BlueShield — the BCBS plan for Maryland, DC, and Northern Virginia — covers Spravato (esketamine) for treatment-resistant depression when prior authorization criteria are met. CareFirst's Spravato criteria are administered through CVS Caremark's Specialty Guideline Management (Guideline 2889-A).
Latest medical review on: May 5th, 2026. Medically reviewed by Instructor in Psychiatry at Harvard Medical School and Lumin Health Co-founder, Chief Medical Officer Dr. Ben Yudkoff.
CareFirst's Spravato coverage criteria, administered via CVS Caremark Specialty Guideline 2889-A:
Augmentation therapy — CareFirst recognizes five forms (per 2889-A):
Alternate pathway for profound depression with persistent suicidal ideation: CareFirst's CVS Caremark guideline 2889-A includes a separate pathway that does not require the standard antidepressant-trial sequence when documented profound depression with persistent suicidal ideation is present. Per 2889-A verbatim, the member must meet all of the following: (i) the prescriber represents that, in the absence of the requested drug, within the next 24 to 48 hours the member will require confinement in an acute care psychiatric institution; (ii) the member has a depressive episode so acute and so severe that the member is not able to participate in self-care (e.g., washing, eating) and is unable to participate at all in their usual daily activities (e.g., work), with persistent thoughts of hopelessness and helplessness as well as anhedonia; (iii) the member has thoughts of dying and/or self-harm for at least some part of each and every day. This pathway is uniquely valuable for crisis-presenting patients.
Authorization duration: Initial authorization is 1 month for treatment of TRD. Continuation authorization is 3 months, granted when there is improvement or sustained improvement from baseline in depressive symptoms documented by standardized rating scales (BDI, HDRS, or MADRS).
Two Maryland insurance statutes apply when a commercial carrier reviews a Spravato prior authorization:
Step therapy prohibition for non-FDA-approved alternatives. Under Maryland Insurance Article §15-142, a commercial carrier may not require step therapy when (a) the step-therapy drug is not FDA-approved for the condition being treated, or (b) the prescriber documents that a covered drug ordered for the same condition within the past 180 days was clinically effective. For Spravato — FDA-approved specifically for treatment-resistant depression — this means a carrier cannot require trials of drugs not FDA-approved for TRD as a precondition.
Grievance and adverse-decision review. Under Maryland Insurance Article §15-10A-02, commercial carriers must issue a standard adverse-determination decision within 30 working days, an emergency review within 24 hours, and a behavioral-health emergency-admission review within 2 hours. After internal review, members can request external review through the Maryland Insurance Administration: 120-day filing window, 60-day decision (4 business days for emergencies).
CareFirst's three-jurisdiction footprint. CareFirst operates as the BCBS carrier for Maryland, the District of Columbia, and Northern Virginia. The CVS Caremark Specialty Guideline 2889-A clinical criteria apply uniformly across the footprint; benefit design (cost-sharing, formulary tier, plan-specific carve-outs) can vary by jurisdiction and specific plan, so members should verify their plan's particulars. DC residents have appeal rights through the DC Department of Insurance, Securities and Banking; Virginia residents through the Virginia Bureau of Insurance.
Spravato treatment at Lumin Health in the Maryland/DMV area is available at Lumin Health Bethesda, which serves patients from across Maryland, the District of Columbia, and Northern Virginia. Lumin Health Bethesda is REMS-certified per FDA requirements.
How CareFirst BCBS compares with other major Maryland commercial payers on published Spravato prior authorization criteria:
Each linked cell opens the full Lumin Health Spravato coverage page for that payer.
Yes. CareFirst administers Spravato prior authorization through CVS Caremark Specialty Guideline 2889-A.
Two antidepressants from at least two different classes (different mechanisms of action), used at the maximally tolerated labeled dose for at least 8 weeks each during the current depressive episode — plus an inadequate response to either an adequate augmentation trial or cognitive behavioral therapy. Both CareFirst and Aetna administer their Spravato PA through CVS Caremark Specialty Guideline 2889-A, so the clinical thresholds are similar.
Initial authorization is 1 month for induction. Continuation authorization is granted in 3-month windows when improvement or sustained improvement on standardized rating scales is documented.
Lumin Health handles everything on your behalf so you don't have to worry. If your prior authorization is denied, our team manages the appeal process directly with CareFirst — you don't need to navigate the paperwork or follow-ups.
Yes — CareFirst is the BCBS carrier for the entire DMV (Maryland, DC, and Northern Virginia), and the CVS Caremark Specialty Guideline 2889-A clinical criteria apply across the footprint. Lumin Health Bethesda serves patients from all three jurisdictions.
Step 1 — File a Level 1 internal appeal. Deadline: 180 days (six months) from receipt of the written claim-denial notification (per CareFirst: "CareFirst must receive your written appeal within 180 days or six months of receiving the written notification of claim denial."). Note: this differs from CareFirst Community Health Plan Maryland Medicaid (90 days) and CareFirst Medicare (60 days) — confirm your product type on your member ID card. Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Mail to: CareFirst Mail Administrator, P.O. Box 14114, Lexington, KY 40512, or use the Member Services Department address printed on your ID card. Phone: the number on your member ID card. Online: secure messaging via My Account at carefirst.com.
Step 2 — Peer-to-peer (P2P) review. CareFirst offers peer-to-peer review at the precertification stage. Your prescriber contacts the CareFirst clinical reviewer named in the denial letter (CareFirst administers Spravato PA criteria through CVS Caremark Specialty Guideline Management). For appeal-stage P2P, include a written request with the appeal submission.
Step 3 — Expedited (urgent) appeal. CareFirst must resolve expedited (urgent) appeals within 72 hours. Call Member Services at the number on your ID card and request expedited review; medical urgency must be documented by your prescriber.
Appeal levels. Most CareFirst commercial plans provide two internal appeal levels. Level 1 is typically resolved within 30 days (or up to 44 days if more clinical information is needed). Level 2 must be filed within the timeframe specified in your Level 1 resolution letter — read the letter carefully and do not delay.
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Maryland external review is administered by the Maryland Insurance Administration (MIA). Filing window: 120 days from the final internal denial. Decision timeline: 60 days standard, 4 business days for emergencies. See Maryland state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. CareFirst's behavioral-health benefits have historically been administered by Magellan/CareFirst Behavioral Health on certain commercial products. Verify the BH-vendor structure on your specific plan summary — this affects which appeal address applies. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the CareFirst BlueCross BlueShield medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
Step 1 — File a Level 1 internal appeal. Deadline: 180 days (six months) from receipt of the written claim-denial notification (per CareFirst: "CareFirst must receive your written appeal within 180 days or six months of receiving the written notification of claim denial."). Note: this differs from CareFirst Community Health Plan Maryland Medicaid (90 days) and CareFirst Medicare (60 days) — confirm your product type on your member ID card. Include the original denial letter, your prescriber's letter of medical necessity, your antidepressant trial history, and any standardized rating-scale documentation that supports the medical-necessity argument.
Submission. Mail to: CareFirst Mail Administrator, P.O. Box 14114, Lexington, KY 40512, or use the Member Services Department address printed on your ID card. Phone: the number on your member ID card. Online: secure messaging via My Account at carefirst.com.
Step 2 — Peer-to-peer (P2P) review. CareFirst offers peer-to-peer review at the precertification stage. Your prescriber contacts the CareFirst clinical reviewer named in the denial letter (CareFirst administers Spravato PA criteria through CVS Caremark Specialty Guideline Management). For appeal-stage P2P, include a written request with the appeal submission.
Step 3 — Expedited (urgent) appeal. CareFirst must resolve expedited (urgent) appeals within 72 hours. Call Member Services at the number on your ID card and request expedited review; medical urgency must be documented by your prescriber.
Appeal levels. Most CareFirst commercial plans provide two internal appeal levels. Level 1 is typically resolved within 30 days (or up to 44 days if more clinical information is needed). Level 2 must be filed within the timeframe specified in your Level 1 resolution letter — read the letter carefully and do not delay.
Step 4 — External review. If the internal appeal is denied, you have the right to an independent external review. Maryland external review is administered by the Maryland Insurance Administration (MIA). Filing window: 120 days from the final internal denial. Decision timeline: 60 days standard, 4 business days for emergencies. See Maryland state-level patient protections above for the full pathway.
Spravato-specific caveat — read your denial letter carefully. Spravato is a REMS-restricted specialty drug. CareFirst's behavioral-health benefits have historically been administered by Magellan/CareFirst Behavioral Health on certain commercial products. Verify the BH-vendor structure on your specific plan summary — this affects which appeal address applies. The exact appeal submission address differs depending on which benefit your plan uses — always confirm the address printed on your specific denial letter before mailing or faxing.
How Lumin Health helps. Lumin Health's prior-authorization team handles appeal submissions, peer-to-peer scheduling with the CareFirst BlueCross BlueShield medical director, and assembles the clinical documentation packet — antidepressant trial history with dosing and duration, baseline and follow-up rating-scale data, prescriber attestation, and any state-specific exception arguments — to maximize the likelihood of overturning the denial.
